Join us for the #IASLC 2026 Hot Topic Meeting on Resistance to Immunotherapy!
🗓️ June 25-27, 2026
📍 Dublin, Ireland
👉 ht26-iaslc.eventsair.site/full-program
@iaslc.bsky.social @patrickforde.bsky.social
@oncoalert.bsky.social @onclive.bsky.social @iaslc.bsky.social
🫁 Most patients with #BRAF - mutant #NSCLC harbor a *non V600* alteration - a major therapeutic blind spot.
Here, we review the complex biology and therapeutic challenges for non-V600 #BRAF–driven #NSCLC
📑
authors.elsevier.com/a/1mTV35Xq2Q...
#BOLEROConsortium
@jtoonline.bsky.social
Just out in @jtoonline.bsky.social !
First-line treatment with #BRAF/#MEK targeted therapy or with (chemo)-immunotherapy results in similar survival outcomes in #BRAF-V600 mutated #NSCLC patients.
#LCSM
www.jto.org/article/S155...
Screenshot of news story
FDA approves a rare novel–novel oncology combination that pairs a first-in-class FAK inhibitor with a MEK–RAF glue inhibitor
www.nature.com/articles/d41...
Verastem’s new therapy for a form of KRAS-mutated ovarian cancer combines the kinase inhibitors defactinib and avutometinib
#BRAF V600E detection and effective BRAF/MEKi treatment in a pure epithelioid #mesothelioma upon progression on ICI (biphasic MPM at baseline).
www.jtocrr.org/article/S266...
The April (and #AACR25) issue of Cancer Discovery is now online! The cover features work by Ling Cai, Nia Hammond, @faubert.bsky.social, @rjdlab.bsky.social & colleagues showing high glucose contribution to the TCA cycle is a feature of aggressive NSCLC - more here: aacrjournals.org/cancerdiscov...
If you’re not angry
you’re not paying attention
#LungCancer #lcsm
Quick shout-out on these two collaborative networks (#BOLERO
and #COALA) during my presentation at #ELCC25.
Looking forward to advancing basic and translational research on #BRAF-mutant #NSCLC and other oncogene-driven #NSCLC.
x.com/JulienMazier...
MARIPOSA final OS analysis
❇️ Significant HR 0.75
❇️ 9% 3yr benefit
❇️ Projected mOS 4 years
❇️ Longer control of CNS disease
❗️At the cost of toxicity
❗️No data on duration of toxicity
❗️PROM and QoL data important
More effective than Osimertinib
Most suitable for higher risk pts
#ELCC25
Three days of great science at the #EACR meeting on #persister cells. We presented our work on models of therapy-residual disease in #BRAF-mutant lung cancer.
Great to have part of the #COALA and #BOLERO crowds in Lyon !
@helloeacr.bsky.social
@ocalvayrac.bsky.social
@maraverlab.bsky.social
Resistance to BRAFi + MEKi in #BRAF V600E melanoma patients is driven by activation of focal adhesion signaling.
Avutometinib (RAF-MEK clamp)
in combination with FAKi reverts resistance to BRAFi plus MEKi or to immunotherapy.
dlvr.it/TJFQ3d
Impressive talk by Lise Mangiante
on tissue ecology from ER+ breast cancer. #CRCL25
www.nature.com/articles/s41...
Great kick-off of the #CRCL25 symposium with a keynote lecture by Joan Massague, on metastasis initiation.
www.crclsymposium2025.fr/en/program/d...
